GPC Satraplatin Data Show Reduction In Disease Progression In Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Data presented at ASCO is part of a Phase III registrational trial for the platinum-based chemotherapy.
You may also be interested in...
FDA Asks For ODAC’s Advice On Composite PFS Endpoint for GPC’s Satraplatin
FDA is seeking the Oncologic Drugs Advisory Committee's opinion on using a composite progression-free survival endpoint as the basis for GPC Biotech's application for Orplatna (satraplatin) to treat androgen-independent prostate cancer in men who failed prior chemotherapy once
FDA Asks For ODAC’s Advice On Composite PFS Endpoint for GPC’s Satraplatin
FDA is seeking the Oncologic Drugs Advisory Committee's opinion on using a composite progression-free survival endpoint as the basis for GPC Biotech's application for Orplatna (satraplatin) to treat androgen-independent prostate cancer in men who failed prior chemotherapy once
FDA Grants Satraplatin Priority Review
GPC Biotech completed rolling NDA in February; action date on novel platinum-based oncologic is Aug. 15.